Healios Seals Deal with FDA for Phase 3 ARDS Study

MT Newswires Live09-10

Healios (TYO:4593) has reached an agreement with the Food and Drug Administration (FDA) on the design of the pivotal Phase 3 REVIVE-ARDS study for acute respiratory distress syndrome (ARDS) caused by pneumonia.

The study will measure the primary endpoint of Ventilator Free Days and include interim analyses at 300 and 400 patients, with a maximum enrollment of 550 patients, according to its filing on Monday.

Healios will also consult Japanese regulatory authorities for conditional approval, based on Phase 2 results and the initiation of the REVIVE-ARDS study.

Healios' shares gained nearly 4% recently.

Price (JPY): $221.00, Change: $+7.0, Percent Change: +3.27%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2466704108?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-10 13:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2466704108","market":"nz","top_or_hot":-1,"title":"Healios Seals Deal with FDA for Phase 3 ARDS Study","media":"MT Newswires Live","content":"<html><body><p> Healios (TYO:4593) has reached an agreement with the Food and Drug Administration (FDA) on the design of the pivotal Phase 3 REVIVE-ARDS study for acute respiratory distress syndrome (ARDS) caused by pneumonia.</p><p>The study will measure the primary endpoint of Ventilator Free Days and include interim analyses at 300 and 400 patients, with a maximum enrollment of 550 patients, according to its filing on Monday.</p><p>Healios will also consult Japanese regulatory authorities for conditional approval, based on Phase 2 results and the initiation of the REVIVE-ARDS study.</p><p>Healios' shares gained nearly 4% recently.</p><p>Price (JPY): $221.00, Change: $+7.0, Percent Change: +3.27%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Healios Seals Deal with FDA for Phase 3 ARDS Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHealios Seals Deal with FDA for Phase 3 ARDS Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-10 13:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Healios (TYO:4593) has reached an agreement with the Food and Drug Administration (FDA) on the design of the pivotal Phase 3 REVIVE-ARDS study for acute respiratory distress syndrome (ARDS) caused by ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARDS","symbol_name":"Aridis制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2466704108","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466704108","pubTimestamp":1725947810,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Healios  has reached an agreement with the Food and Drug Administration  on the design of the pivotal Phase 3 REVIVE-ARDS study for acute respiratory distress syndrome  caused by pneumonia.The study will measure the primary endpoint of Ventilator Free Days and include interim analyses at 300 and 400 patients, with a maximum enrollment of 550 patients, according to its filing on Monday.Healios will also consult Japanese regulatory authorities for conditional approval, based on Phase 2 results and the initiation of the REVIVE-ARDS study.Healios' shares gained nearly 4% recently.Price : $221.00, Change: $+7.0, Percent Change: +3.27%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARDS":"Aridis制药","BK4139":"生物科技"},"translate_title":"Healios与FDA就ARDS 3期研究达成协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARDS":1},"content_text":"Healios (TYO:4593) has reached an agreement with the Food and Drug Administration (FDA) on the design of the pivotal Phase 3 REVIVE-ARDS study for acute respiratory distress syndrome (ARDS) caused by pneumonia.The study will measure the primary endpoint of Ventilator Free Days and include interim analyses at 300 and 400 patients, with a maximum enrollment of 550 patients, according to its filing on Monday.Healios will also consult Japanese regulatory authorities for conditional approval, based on Phase 2 results and the initiation of the REVIVE-ARDS study.Healios' shares gained nearly 4% recently.Price (JPY): $221.00, Change: $+7.0, Percent Change: +3.27%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2466704108"}